“We can only strike one partnership deal”
Revenue must be raised slightly if Bavarian Nordic is to meet its full-year targets, says the company’s CFO, who also unveils part of the strategy for one of the major hopes in its pipeline.
BY STEFAN SINGH KAILAY
Bavarian Nordic struck a historic deal with drug giant Bristol-Myers Squibb in the first quarter of the year, deliveries of the company’s small pox vaccine have been running according to plan, as has a development deal with Janssen for a vaccine against Ebola virus.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bavarian strikes historic Prostvac deal
For abonnenter
”It’s a top five deal”
For abonnenter
Bavarian: Most compelling results so far
For abonnenter
